4D Molecular licenses R100 vector to Astellas for up to $300M per target in ophthalmic gene therapies

4D Molecular Therapeutics, Inc.

$20M upfront from Astellas; eligible for up to $42.5M in option/target substitution fees and $300M per target in milestones.
Astellas gains exclusive worldwide license to 4DMT's R100 vector for up to three ophthalmic rare monogenic disease targets.
Tiered royalties from mid-single digits to double-digit sub-teen percentage on net sales; subject to reductions.
Astellas must use commercially reasonable efforts to develop and commercialize in US and at least two major EU markets.
4DMT agreed not to commercialize competing products for 7 years (through July 2030).

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.